This 2023 narrative review by Mima et al. explores the potential renoprotective effects of incretin-based therapies—specifically GLP-1 receptor agonists and DPP-4 inhibitors—in managing diabetic kidney disease (DKD), a leading cause of chronic kidney disease and end-stage renal disease. The authors discuss how GLP-1 receptor agonists may exert vasotropic actions that
